Core Insights - HBC has appointed Paul Bruhn as Head of New Business Development, bringing over 25 years of experience in healthcare and medical nutrition [1][2] - The company has developed a unique portfolio of bioactive ingredients derived from salmon, including OmeGo®, ProGo®, NT-II™, and PetGo®, which are scientifically backed and sustainable [3][4] - HBC emphasizes scientific evidence in its product development, leading to academic partnerships and the identification of unique health benefits [5][6] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources, upcycling side streams of the salmon industry [3][6] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [7] Product Portfolio - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [4][5] - OmeGo® is noted for its full spectrum of Omega fatty acids, being 100% natural and clinically proven for various health benefits [3][5] Market Focus - HBC aims to address market needs for clinically backed nutrition sources, particularly in Asia, China, and the ANZ region [2][3] - The company is exploring potential therapeutics through its biotech-focused spin-off, HBC Immunology, targeting prostate and ovarian cancer, as well as asthma treatments [6]

A journey into the history of nutrition science in the US suggests that MAHA would make more sense without the ‘A’ for Again. https://t.co/N1TiUDRfgN ...